Needham Maintains Buy on Sarepta Therapeutics, Raises Price Target to $235
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $166 to $235.
June 21, 2024 | 10:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has maintained a Buy rating on Sarepta Therapeutics and increased the price target from $166 to $235, indicating strong confidence in the company's future performance.
The increase in the price target from $166 to $235 by a reputable analyst suggests a positive outlook for Sarepta Therapeutics. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100